Key result
Exhaled breath condensate periostin levels and tissue periostin expression were significantly higher in patients with asthma compared to those with chronic obstructive pulmonary disease.
Cross-Sectional (n=72)
No
Absolute Event Rate: 1.5% vs 0.2%
p-value: p=<0.001
Periostin levels in exhaled breath condensate are higher in asthma than COPD and may serve as a noninvasive surrogate marker for tissue periostin expression.
Periostin may aid noninvasive asthma-COPD differentiation; cross-sectional data leave diagnostic utility open to validation.
INTRODUCTION: Periostin is considered to be a marker of eosinophilic inflammation in patients with asthma. However, there are no literature data on periostin in patients with chronic obstructive pulmonary disease (COPD). OBJECTIVES The aim of the study was to evaluate periostin expression and to compare its concentrations in various materials in patients with mild-to-moderate asthma and COPD, as well as to evaluate the potential association between periostin and clinical features of both diseases. PATIENTS AND METHODS: Using an enzyme-linked immunosorbent assay, we measured periostin concentrations in serum, induced sputum (IS), exhaled breath condensate (EBC), and bronchoalveolar lavage fluid (BALF) as well as periostin expression in bronchial biopsy samples in 24 patients with asthma, 36 patients with COPD, and 12 controls. Correlations between periostin levels in different materials were also analyzed and periostin concentrations were compared between patients with asthma and those with COPD. RESULTS: Periostin levels were detectable in serum, IS, EBC, and BALF from patients with asthma, COPD, and controls. EBC periostin levels correlated with tissue periostin expression and were significantly higher in asthma than in COPD (P = 0.04). Periostin expression in bronchial mucosa was higher in asthma than in COPD (P <0.001), as well as in asthma and COPD patients compared with controls (P <0.001). No significant correlations between tissue periostin expression and BALF, IS, or serum periostin levels were found. There were no differences in serum, IS, BALF, or EBC periostin concentrations between patients with different phenotypes of both diseases. CONCLUSIONS: Periostin may be detected not only in serum, IS, and airway tissue samples, but also in EBC and BALF. EBC periostin levels and tissue periostin expression are higher in patients with asthma than in those with COPD. EBC periostin levels may serve as a potential surrogate marker for tissue periostin expression.
No takes yet. Share an insight, caveat, or question.
Górska et al. (2016) conducted a cross-sectional in Asthma and Chronic Obstructive Pulmonary Disease (COPD) (n=72). Asthma vs. COPD and healthy controls was evaluated on Exhaled breath condensate (EBC) periostin levels (p=<0.001). Exhaled breath condensate periostin levels and tissue periostin expression were significantly higher in patients with asthma compared to those with chronic obstructive pulmonary disease.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: